Zoetis (ZTS) Projected to Post Quarterly Earnings on Thursday

Zoetis (NYSE:ZTS - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect Zoetis to post earnings of $1.37 per share and revenue of $2.31 billion for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis's revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.36 EPS. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Zoetis Stock Performance

Zoetis stock traded down $2.75 during trading hours on Friday, hitting $171.37. The company had a trading volume of 1,927,109 shares, compared to its average volume of 2,620,628. The firm has a 50-day moving average of $169.34 and a 200 day moving average of $179.28. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm has a market cap of $77.32 billion, a PE ratio of 32.21, a PEG ratio of 2.72 and a beta of 0.90. Zoetis has a one year low of $144.80 and a one year high of $200.53.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis's dividend payout ratio (DPR) is currently 37.59%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research reports. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. Finally, Morgan Stanley decreased their target price on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Zoetis presently has an average rating of "Buy" and an average price target of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.